NCT05041036Available不适用
Individual Patient Compassionate Use of Nirogacestat
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany0 个研究点开始时间: 2021年9月10日最近更新:
适应症
相关药物
试验速览
研究概览
简要总结
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
- •Patient does not qualify to participate in an ongoing clinical trial.
排除标准
- 未提供
研究者
相似试验
Available
不适用
Individual Patient Compassionate Use of MirdametinibNeurofibromatosis Type 1-Associated Plexiform NeurofibromasHistiocytic NeoplasmOther MAP-K Pathway Driven DiseasesNCT05028166SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
No Longer Available
不适用
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029HIVNCT00801515ViiV Healthcare
已完成
不适用
Collaborative care program for patients with treatment resistant schizophrenia.long-lasting psychosistreatment resistant schizophrenia10039628NL-OMON52870Reinier van Arkelgroep (Den Bosch)3
Available
不适用
Fremanezumab Managed Access Program for Pediatric PatientsMigraineNCT03539393Teva Branded Pharmaceutical Products R&D LLC
No Longer Available
不适用
Compassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyEpilepsyNCT03532516UCB Biopharma SRL